RT Book, Section
A1 Leavitt, Andrew D.
A1 Price, Erika Leemann
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1184168571
T1 Acquired Disorders of Platelet Function
T2 Current Medical Diagnosis & Treatment 2022
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264269389
LK accessmedicine.mhmedical.com/content.aspx?aid=1184168571
RD 2024/04/24
AB Platelet  dysfunction  is  more  commonly  acquired  than  inherited;  the  widespread  use  of  platelet-altering  medications  accounts  for  most  of  the  cases  of  qualitative  defects  (eTable  14–2).  In  cases  where  platelet  function  is  irreversibly  altered,  platelet  inhibition  typically  recovers  within  7–9  days  following  discontinuation  of  the  drug,  which  is  the  time  it  takes  to  replace  all  of  the  impaired  platelets  with  newly  produced  platelets.  In  cases  where  platelet  function  is  non-irreversibly  affected,  platelet  inhibition  recovers  with  clearance  of  the  drug  from  the  system.  Transfusion  of  platelets  may  be  required  if  clinically  significant  bleeding  is  present.